Litigation vs Licensing for Pharma & Biotech Patents in Canada: When to Sue, When to Licence

Every pharma or biotech patent holder in Canada eventually faces the same fork in the road: enforce the patent through litigation, or monetise it through a licence. The choice confronts originators watching a generic challenger file a Notice of Allegation under the Patented Medicines (Notice of Compliance) Regulations, non-resident rights holders weighing Canadian market entry, and CFOs running cost-benefit analyses on an aging portfolio. In 2026 the calculus has shifted, patent term adjustment has extended enforceable exclusivity for many drugs, third-party litigation funding is more accessible than ever, and the Competition Bureau is actively monitoring pharma settlement terms.

This article delivers a practitioner-grade decision framework for litigation vs licensing Canada pharma patents, complete with cost benchmarks, a dimension-by-dimension comparison, and an actionable checklist you can take straight into a boardroom or a first meeting with counsel.

Option A, Patent Enforcement Through Litigation

Patent litigation in Canada is an infringement action brought in the Federal Court of Canada under the Patent Act (R.S.C., 1985, c. P-4). For pharmaceutical patents, enforcement is tightly linked to the PM(NOC) Regulations, which create a statutory bridge between patent rights and Health Canada’s drug-approval process. An originator that lists its patents on the Patent Register can commence an action under section 6 of the PM(NOC) Regulations after receiving a Notice of Allegation from a generic manufacturer seeking market authorisation. The Federal Court may grant a stay of the Notice of Compliance for up to 24 months while the action is pending, effectively blocking generic market entry during that window.

Outside the PM(NOC) regime, a patent holder can bring a standalone infringement action seeking any combination of injunctive relief, compensatory damages, or an accounting of profits under sections 54 and 55 of the Patent Act. The Federal Court has exclusive jurisdiction over validity challenges but shares infringement jurisdiction with provincial superior courts, though pharma litigants overwhelmingly choose the Federal Court for its specialist IP bench and established procedural framework.

Litigation suits a patent holder that meets four criteria simultaneously:

• Clear infringement. A well-constructed claims chart maps the competitor product to each essential claim element.
• Strong validity position. The patent has survived re-examination or prior challenge, or the prosecution history supports defensibility.
• High commercial upside. Lifetime product margins are large enough to justify multi-year legal costs, typically products with annual Canadian sales well above $10 million.
• Capacity to fund. The patent holder has internal budget, insurance, or access to third-party litigation funding in Canada.

The remedies available on success are powerful: a permanent injunction that removes the infringing product from the Canadian market, damages calculated on either a lost-profits or reasonable-royalty basis, or an accounting of the infringer’s profits. In PM(NOC) actions, the market-blocking effect of the 24-month stay can be as commercially valuable as the final judgment itself. The trade-off is uncertainty, trial outcomes depend on claim construction, expert credibility, and judicial discretion, and timelines that typically run 12 to 36 months to trial in the Federal Court, with appeals adding a further 12 to 18 months.

Option B, Licensing, Monetisation, and Structured Settlement

Licensing converts a patent right into a revenue stream without the binary win-or-lose risk of trial. The owner grants a counterparty permission to practise the invention in exchange for consideration, typically a running royalty, an up-front lump sum, milestone payments, or a combination. In pharma, licensing is also a common endgame for litigation that settles before or during trial, where the settlement takes the form of a licence coupled with a covenant not to sue.

The principal licence structures used in Canadian pharma transactions include:

• Exclusive licence. One licensee receives sole rights in a defined field, territory, or indication. Commands the highest royalty rate but limits the licensor’s ability to grant further rights.
• Non-exclusive licence. Multiple licensees operate simultaneously, generating broader market penetration at lower per-licensee rates.
• Field-of-use or territory carve-outs. The licensor retains enforcement rights for unlicensed fields or geographies, preserving future litigation options.
• Structured settlement with authorised-generic provisions. The originator permits a generic to enter at a specified date before patent expiry, with royalty payments bridging the gap, common in PM(NOC) resolutions.

Key negotiation levers include royalty base definitions (net sales vs. gross), most-favoured-nation clauses, step-in rights if the licensee defaults, sublicence revenue-sharing percentages, and audit rights. A well-drafted licence can also carve out the right to sue third-party infringers, preserving enforcement optionality.

When to licence a patent in Canada comes down to practical triggers: the remaining patent term is short, damages projections are modest, litigation probability of success is uncertain, the patent holder needs near-term cash flow, or the competitive landscape favours collaboration over exclusion. Licensing is also the safer path when a structured settlement would attract Competition Bureau scrutiny, a properly framed licence avoids many of the anticompetitive red flags that reverse-payment or pay-for-delay deals invite.

Patent Enforcement vs Licensing Canada, Side-by-Side Comparison

The table below sets out the core dimensions that drive the litigation vs licensing decision for Canadian pharma patents. Use it as a rapid reference before reading the detailed dimension analysis that follows.

Three headline takeaways:

• Litigation delivers the highest potential upside, market exclusivity plus damages, but carries binary risk and costs that can exceed $4 million for complex pharma cases.
• Licensing provides certainty and speed, and is the preferred route when remaining patent term, litigation probability, or commercial margins do not support a full enforcement action.
• The two paths are not mutually exclusive: many pharma patent disputes begin as litigation and resolve through a structured settlement licence, and a well-drafted licence can preserve the right to sue third parties.

Dimension-by-Dimension Analysis, Pros and Cons of Licensing vs Litigation

Cost, Patent Litigation Costs Canada vs Licensing Expenses

Cost is the single largest variable separating the litigation route from the licensing route. Pharma patent suits in the Federal Court involve layers of expense that compound rapidly once discovery begins. The table below breaks down typical 2026 cost ranges for each phase.

Discovery and expert fees together account for the bulk of patent litigation costs in Canada. E-discovery volumes in pharma cases, where regulatory filings, lab notebooks, and correspondence with Health Canada must be reviewed, routinely push document-review costs past $500,000. Economic experts retained to quantify damages or a reasonable royalty add another significant layer. These cost drivers make the funding question central to any enforcement decision.

Timing, Court Timetables and the PM(NOC) Effect

Federal Court patent trials typically reach hearing within 18 to 30 months of filing, depending on case complexity and court scheduling. The Court’s practice directions for intellectual property proceedings set out a managed timetable that includes mandatory case-management conferences and fixed deadlines for expert reports. Appeals to the Federal Court of Appeal add 12 to 18 months.

• PM(NOC) actions compress timing commercially. Once an originator commences an action under the Regulations, Health Canada will not issue a Notice of Compliance to the generic for up to 24 months or until the action is resolved, whichever comes first. This stay period functions as a de facto injunction during the litigation window.
• Licensing negotiations typically close in one to six months, with execution of a term sheet possible in weeks for parties with aligned commercial interests.

Enforceability and Regulatory Burden, The PM(NOC) Dimension

The Patented Medicines (Notice of Compliance) Regulations (SOR/93-133) are the central regulatory mechanism connecting patent rights to drug-market access in Canada. An originator that has listed its patents on the Patent Register receives the right to commence an action when a generic files a Notice of Allegation asserting non-infringement or invalidity. The 24-month stay that follows is the most powerful short-term remedy available to an originator, it delays generic competition without requiring the patent holder to prove its case on the merits.

Settlement of PM(NOC) enforcement vs settlement disputes increasingly attracts regulatory attention. The Competition Bureau has publicly stated that it monitors pharma patent settlement agreements for anticompetitive effects, particularly reverse-payment or pay-for-delay terms. Any settlement that includes value transfers from originator to generic, whether cash, authorised-generic licences, or supply agreements, should be reviewed against the Competition Bureau’s enforcement framework before execution.

Liability and Legal Risk

Litigation exposes the patent holder to counterclaims, principally invalidity and, less commonly, allegations of inequitable conduct or abuse of the patent system. An adverse invalidity finding eliminates the patent entirely, not just against the current defendant. Cost orders in the Federal Court, while typically modest relative to total legal spend, add financial risk. On the licensing side, the primary risk is counterparty default or underperformance, mitigated through audit rights, minimum-royalty floors, and termination-for-breach provisions.

Tax and Accounting Implications

The tax treatment of litigation proceeds and licensing revenue differs in ways that can materially affect net returns, particularly for non-resident patent holders.

• Damages from litigation are generally treated as taxable income in Canada. Where the damages represent lost profits, they are taxed at ordinary income rates. Legal costs incurred to earn income may be deductible as current expenses, but costs related to capital-property disputes may need to be capitalised, the classification is fact-specific and requires guidance from a tax adviser familiar with CRA positions.
• Royalty income from licences is treated as income for tax purposes. For non-resident licensors, Canada imposes a withholding tax on royalty payments, subject to reduction under applicable tax treaties. Structuring licence payments as milestone lump sums versus running royalties can affect cash-flow timing and withholding obligations.
• Cross-border considerations. Foreign patent holders licensing into Canada should confirm treaty withholding rates and transfer-pricing compliance before finalising terms.

Funding and Cost Mitigation, Litigation Funding Canada

Third-party litigation funding has become a realistic option for Canadian pharma patent disputes. Funders provide non-recourse capital to cover legal fees and disbursements in exchange for a share of any recovery. The Canadian Bar Association and provincial law societies have addressed the ethical framework for funded litigation, and early indications suggest that the professional-conduct guidance supports properly structured funding arrangements provided the funder does not exercise control over litigation strategy.

Funding models available in 2026 include:

• Single-case funding. The funder finances one action and receives a percentage of recovery or a multiple of its investment.
• Portfolio funding. A funder commits capital across multiple cases held by the same rights holder, spreading risk and often accepting lower per-case returns.
• Contingency or hybrid fee arrangements with counsel. The law firm accepts a reduced hourly rate plus a success premium, sometimes combined with third-party funding for disbursements.

Before engaging a funder, counsel should evaluate offers against the following checklist:

• What percentage of recovery or return multiple does the funder require?
• Does the funder retain any control over litigation strategy or settlement decisions?
• What confidentiality obligations apply to case information shared with the funder?
• Is the funding commitment irrevocable, or can the funder withdraw under defined circumstances?
• How does the funder’s capital structure affect its ability to meet ongoing commitments?
• What reporting and budget-approval mechanisms are required?
• Does the funder’s participation create any conflicts with other portfolio investments?
• How are adverse cost orders handled, does the funder indemnify or share the risk?

What Changes in 2026, Policy, Funding, and Cost Signals

Four developments have meaningfully shifted the litigation vs licensing calculus for Canadian pharma patents since 2024.

Patent term adjustment extends enforceable exclusivity. Canada’s patent term adjustment provisions, implemented effective January 1, 2025, allow patent holders to recover time lost to unreasonable delays in patent examination. For pharma compounds that spent years in prosecution, PTA can add months or years to the enforceable patent term, directly increasing the damages horizon available through litigation and the royalty base available through licensing. The Canadian Intellectual Property Office (CIPO) administers PTA under the amended Patent Act.

Third-party litigation funding is more accessible and professionalised. The entry of institutional funders into the Canadian market, combined with clearer ethical guidance from the CBA and provincial law societies, has lowered the barrier to funding patent enforcement. Industry observers expect funding availability to continue expanding, particularly for pharma portfolios where damages are quantifiable and market data is robust.

Competition Bureau scrutiny of pharma settlements has intensified. The Bureau has made public statements about monitoring settlement agreements between originators and generics for anticompetitive effects. The likely practical effect is that any settlement containing a value transfer to the generic, cash, supply agreements, or authorised-generic rights, will need to be structured with competition-law advice to avoid triggering a Bureau inquiry.

Federal Court procedural improvements support faster, more predictable patent trials. Updated practice directions for IP proceedings, specialist case-management protocols, and the Court’s emphasis on proportionality in discovery have contributed to more predictable timelines and, in some cases, reduced costs for well-managed cases.

Litigation vs Licensing: Decision Framework for Canada Pharma Patents

Use the framework below to determine whether enforcement or licensing is the stronger path for your specific patent and market position. The decision turns on three threshold questions, followed by a detailed trigger-condition assessment.

Three-question decision funnel:

1. Is infringement clear? Can you map every essential claim element to the competitor’s product or process with documentary evidence?
2. Does remaining enforceable exclusivity exceed three years? Include any patent term adjustment. If less than three years remain, the litigation timeline may consume most of the exclusivity period.
3. Does the estimated net present value of exclusivity exceed total litigation costs multiplied by a risk factor of 2–3×? If projected NPV is at least two to three times the high-end litigation cost estimate, the economics favour enforcement. Below that threshold, licensing typically delivers better risk-adjusted returns.

If the answer to all three questions is yes, litigation is the recommended path. If any answer is no, licensing or a structured settlement will generally produce a superior outcome. Refine the analysis using the trigger conditions below.

Choose litigation when:

• Infringement is well-documented and claim validity has been tested or is strongly defensible
• The product generates annual Canadian sales sufficient to justify $1 m+ in legal costs
• Preserving market exclusivity is the strategic priority, the originator’s commercial model depends on being the sole supplier
• A PM(NOC) action is available and the 24-month stay provides immediate commercial protection
• Third-party litigation funding is available, eliminating or reducing the cash-flow burden
• Setting a precedent matters, the patent holder needs a court ruling to deter future challengers across a portfolio
• The Competition Bureau risk of a structured settlement is higher than the litigation risk itself

Choose licensing when:

• Remaining patent term is short (fewer than three years) and litigation timelines would consume most of the exclusivity window
• Validity is uncertain, prior art or prosecution-history issues weaken the patent’s defensive position
• The patent holder needs near-term cash flow or is monetising a non-core asset
• Damages projections are modest relative to enforcement costs
• Multiple potential licensees exist, making a non-exclusive programme more lucrative than excluding any single competitor
• A structured settlement with an authorised-generic entry date delivers better risk-adjusted economics than trial
• The patent holder wants to preserve a commercial relationship with the counterparty

When to Engage a Lawyer for This Decision

The litigation-versus-licensing decision is not one to make internally without specialist patent counsel. Engage a lawyer immediately in any of the following situations:

• You receive a Notice of Allegation under the PM(NOC) Regulations. Statutory deadlines apply, an originator has 45 days from receiving the NOA to commence an action in the Federal Court in order to trigger the 24-month stay.
• You discover evidence of commercial infringement, a competitor product on the market, a regulatory submission referencing your compound, or a supply agreement that indicates manufacture of a patented molecule.
• You are approached by a potential licensee or receive an unsolicited licensing proposal. Before disclosing any information, counsel should assess the patent’s enforceability and establish a confidentiality framework.
• You are evaluating litigation funding offers. The terms of a funding agreement, control rights, return multiples, confidentiality, directly affect litigation strategy and must be reviewed by independent counsel.
• The estimated value of the patent or its market exceeds $5 million. At this threshold, the cost of a wrong decision (forfeited exclusivity, undervalued licence, or wasted litigation spend) justifies specialist advice.

Prepare the following materials before your first meeting with counsel: a claims chart mapping the patent to the competitor product, three years of commercial sales data for the patented product, the patent prosecution history file, competitor product specifications or regulatory filings, and any relevant regulatory or market-entry timelines.

Conclusion, Making the Litigation vs Licensing Decision for Canada Pharma Patents

The choice between litigation and licensing for a Canadian pharma or biotech patent is ultimately a risk-adjusted return calculation. Litigation delivers the highest potential payoff, injunctive relief, substantial damages, and preserved market exclusivity, but it demands significant capital, tolerance for uncertainty, and a timeline measured in years. Licensing provides speed, certainty, and guaranteed revenue, at the cost of capping upside and sharing the market.

In 2026, the decision environment has tilted modestly in favour of enforcement for well-capitalised patent holders: patent term adjustment has extended enforceable exclusivity, litigation funding has made non-recourse financing realistic, and the PM(NOC) 24-month stay remains the most potent short-term market-protection tool available. At the same time, Competition Bureau monitoring of pharma settlements means that any licensing or settlement path must be structured with competition-law advice from the outset.

Apply the three-question decision funnel above, clear infringement, sufficient remaining term, and NPV exceeding litigation costs by a factor of two to three, and use the trigger-condition checklists to confirm your path. Where the answer is ambiguous, or where a PM(NOC) Notice of Allegation introduces statutory deadlines, engage specialist patent litigation counsel without delay. The cost of a wrong decision on litigation vs licensing Canada pharma patents is measured not in legal fees alone, but in years of lost exclusivity or foregone revenue that no retrospective remedy can recover.

Sources

1. Patent Act (R.S.C., 1985, c. P-4), Justice Laws
2. Patented Medicines (Notice of Compliance) Regulations, Justice Laws
3. Innovation, Science and Economic Development Canada (CIPO), Patents
4. Competition Bureau Canada
5. Federal Court of Canada, Practice Directions
6. Canadian Bar Association
7. Canada Revenue Agency